2Shen J,Valero V,Buchholz TA,et al.Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy[J].Ann Surg Oncol,2004,11(9):854-860.
2Buchholz TA, Hunt KK, Whitman Gj, et al. Neoadjuvant chemotherapy for breast carcinoma : muhidisciplinary considerations of benefits and risks. Cancer, 2003, 15(6):1150-1160.
3Fisher B, Anderson S. Twenty - year follow - up a randomized trial comparing total mastectomy, Lumpectomy, and Lumpectojmy plus irradiation for the treatment of invasive breast cancer. N Engl J Med,2002, 347(16) : 1233-1241.
4Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor, Cancer Rcs, 1979, 39(10) :3861-3865.
5Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases, Cancer Res, 1983,43(4):1488-1492.
6Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local- regional disease in women with operable breast carcinoma: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol, 1997,15 : 2483-2493.
7Kurtz JM, Kinkle K. Breast conservation in 21 st century. Euro J Cancer,2000,36,1919-1924.
8Mauriac L, MacGragan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3cm: a unicentre randomized trial with a 124-month median follow-up. Institute Bergonie Bordeaux Group Sein. Ann Oncol, 1999,10:47-52.
5SAKORAFAS GH, SAFIOLEAS M. Breast cancer surgery: an historical narrative. Part 1. From prehistoric times to Renaissance[J]. Eur J Cancer Care ( Engl), 2009,18 ( 6 ): 530- 544.
6RIGAS JR, DRAGNEV KH, BUBIS JA. Docetaxel in the treatment of esophageal cancer[J]. Semin One, 2005,32 (4) : 39-51.
7Therasse P, Arbuek SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Nal Cancer Inst,2000,92 ( 1 ) :205-216.
8Ellis M J, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res,2003,63 (19) :6523-6524.
9Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal-women with advanced breast cancer : results of a phase Ⅲ study of the international letrozole breast cancer group. Clin Oncol,2001, 19(10) :2596-2606.
